PMID- 21538973
OWN - NLM
STAT- MEDLINE
DCOM- 20111103
LR  - 20110606
IS  - 1520-6033 (Electronic)
IS  - 1520-6033 (Linking)
VI  - 27
IP  - 3
DP  - 2011 May-Jun
TI  - Recombinant monomeric CD40 ligand for delivering polymer particles to dendritic 
      cells.
PG  - 830-7
LID - 10.1002/btpr.595 [doi]
AB  - Dendritic cells (DCs) are considered the most efficient antigen-presenting cells 
      and are therefore ideal targets for in vivo delivery of antigen for vaccines. We 
      are investigating the strategy of using CD40 ligand (CD40L) as a targeting moiety 
      because this protein has the potential to not only target DCs, but also stimulate 
      cell maturation, leading to more potent immune responses. We have shown that a 
      recombinant, monomeric CD40 ligand fusion protein conjugated to polystyrene 
      micro- and nanoparticles led to significantly enhanced uptake by DCs in vitro. 
      This enhancement was observed for particles of both sizes and in both a murine DC 
      cell line and primary DCs. The uptake appeared to be specifically mediated by 
      CD40L binding to CD40 expressed on DCs. Enhanced uptake of nanoparticles in 
      draining lymph nodes of mice was not observed, however, 48 hours after 
      subcutaneous injection. These findings suggest that CD40 ligand may be a 
      potentially useful targeting moiety for delivery of particulate vaccines to DCs, 
      and that further optimization of both CD40L and the polymer carriers is necessary 
      to achieve efficacy in vivo.
CI  - Copyright (c) 2011 American Institute of Chemical Engineers (AIChE).
FAU - Palumbo, R Noelle
AU  - Palumbo RN
AD  - Dept. of Biomedical Engineering, University of Minnesota, Minneapolis, MN 55455, 
      USA.
FAU - Nagarajan, Lakshmi
AU  - Nagarajan L
FAU - Wang, Chun
AU  - Wang C
LA  - eng
GR  - R01CA129189/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20110502
PL  - United States
TA  - Biotechnol Prog
JT  - Biotechnology progress
JID - 8506292
RN  - 0 (Drug Carriers)
RN  - 0 (Polymers)
RN  - 0 (Recombinant Proteins)
RN  - 0 (Vaccines)
RN  - 147205-72-9 (CD40 Ligand)
SB  - IM
MH  - Animals
MH  - Biological Transport
MH  - CD40 Ligand/*therapeutic use
MH  - Cells, Cultured
MH  - Dendritic Cells/*metabolism
MH  - *Drug Carriers
MH  - Drug Delivery Systems/*methods
MH  - Lymph Nodes/metabolism
MH  - Mice
MH  - Particle Size
MH  - Polymers/*administration & dosage/metabolism
MH  - Recombinant Proteins
MH  - Vaccines
EDAT- 2011/05/04 06:00
MHDA- 2011/11/04 06:00
CRDT- 2011/05/04 06:00
PHST- 2010/01/29 00:00 [received]
PHST- 2010/11/24 00:00 [revised]
PHST- 2011/05/04 06:00 [entrez]
PHST- 2011/05/04 06:00 [pubmed]
PHST- 2011/11/04 06:00 [medline]
AID - 10.1002/btpr.595 [doi]
PST - ppublish
SO  - Biotechnol Prog. 2011 May-Jun;27(3):830-7. doi: 10.1002/btpr.595. Epub 2011 May 
      2.